Physician profile
David Eldridge
NPI 1841260254
$2,732.19
in general payments reported to CMS, 2019-2025
10 companies · $886 in 2025
The $886 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $111 · 2021: $139 · 2022: $377 · 2023: $721 · 2024: $353 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $841.96 | 2019-2025 | Total30, Dailies Total1, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $499.78 | 2024-2025 | Infuse, Xiidra, Miebo |
| Johnson & Johnson Vision Care, INC. | $460.46 | 2023-2025 | Acuvue |
| Glaukos Corporation | $351.03 | 2022-2025 | Kxl System (Not Refurbished) |
| Abbvie INC. | $330.94 | 2022-2025 | |
| Allergan, INC. | $143.85 | 2021-2022 | |
| Coopervision INC. | $31.11 | 2023 | Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $28.13 | 2025 | Xdemvy |
| Abb Con-Cise Optical Group LLC | $23.29 | 2019 | |
| Oyster Point Pharma, INC. | $21.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Eldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.